Pyrazinone Crystal Forms for Selective FGFR2/3 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies targeting fibroblast growth factor receptors (FGFR) for treating cancer lack specificity and stability, particularly in inhibiting FGFR tyrosine kinases effectively.
Innovation Solution
A novel crystal form of a pyrazin-2(1H)-one compound, characterized by specific X-ray powder diffraction patterns and thermal analysis, is developed, which forms stable drug forms with improved inhibitory activity against FGFR2 and 3 over FGFR1 and 4, and exhibits good pharmacokinetic properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional FGFR inhibitors are used, then FGFR tyrosine kinases can be inhibited, but the inhibitors lack specificity and stability
Solution Approach 1:
The patent changes the chemical structure parameters of the FGFR inhibitor by introducing specific substituents (R1-R6 groups) at defined positions on the pyrazinone core structure. This structural parameter optimization enables the compound to achieve both high stability and specificity by forming precise molecular interactions with the target kinase while resisting metabolic degradation.
Solution Approach 2:
The patent applies local quality by introducing different substituent groups (R1-R6) at specific positions on the pyrazinone molecule. Each substituent can be independently optimized to enhance specific properties: electron-withdrawing groups may improve metabolic stability, while aromatic substituents may enhance binding specificity to FGFR2/3 over FGFR1/4.
2Adaptability or versatility
If current FGFR therapies are applied, then cancer treatment can be achieved, but the inhibitory activity lacks selectivity among different FGFR isoforms
Solution Approach 1:
The patent optimizes selectivity by systematically varying substituent parameters at positions R1-R6 on the pyrazinone scaffold. Specific combinations of these substituents are designed to exploit subtle differences in the binding pockets of FGFR2 and FGFR3 compared to FGFR1 and FGFR4, achieving preferential inhibition of the former while maintaining potent kinase inhibitory activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystal forms of the compound demonstrate enhanced stability, better inhibitory activity against FGFR, and higher selectivity for FGFR2 and 3, along with favorable pharmacokinetic profiles, making them effective candidates for treating FGFR-related diseases.
Implementation Method 1
the compound of formula (II) and a crystal form thereof... exhibit better inhibitory activity against wild-type FGFR, and the selectivity of FGFR2 and 3 against FGFR1 and 4 is higher
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
Provided are crystalline forms of pyrazine-2(1H)-ketone compound and a preparation method thereof; specifically disclosed are a method for preparing the compound of formula (II) and crystalline forms thereof.